The United Kingdom and the United States have reached a significant trade agreement that will ensure no import taxes on UK pharmaceutical products being sold in the American market.
The Terms of the Deal
As part of the deal, the UK has pledged to increase funding on pharmaceuticals through the National Health Service (NHS). This commitment secures that duties on these vital exports will be held at nothing for a period of 36 months.
This deal comes after previous statements to significantly raise tariffs on branded pharmaceutical products, with figures floated up to one hundred percent.
"This deal with the UK bolsters the worldwide climate for new treatments and brings much-needed fairness to transatlantic medicine commerce," a statement said.
Trade Importance
Pharmaceuticals constitute one of the UK's largest exports to the America, which is by far the largest market for large UK drugmakers.
Statistics reveal that in the 12 months to the end of September, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This amount made up a significant portion of all goods exports in that span.
"This guarantee protects employment, stimulates capital expenditure and facilitates the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Detailed NHS Changes
The agreement involves several key changes from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a target to raise total public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The sum drug companies must return to the NHS to stay within budget will be capped at 15%. Last year, repayments were more than 20%.
Industry Background
This agreement follows a protracted row between the sector and the British authorities over drug pricing and approval rates.
This friction were exacerbated by arguments that US patients were charged significantly more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several large drug company projects in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been pledged toward US facilities.
A senior figure acknowledged that the NHS must increase expenditure on medicines, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.
